EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SLC15A3-mediated dipeptide metabolism confers antimetabolite resistance in lymphoma via mTORC1 activation

Haojun Yang, Vincenzo Andrea Zingaro, Kevin Boardman, Ashish Noronha, Ekin Guney, Lingru Xue, Saishma Hoigebazar, Isabelle Liu, Sohit Miglani, Siyu Chen, Hieu Vu, Kwun Wah Wen und 4 weitere

Journal of Clinical Investigation · 15.07.2026 · 136 (14)

DOI: 10.1172/jci199709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.07.2026. Verfasst von Haojun Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, and. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 1, Drug Resistance, Neoplasm, Dipeptides, Lymphoma, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIDDK NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimetabolites, chemotherapy targeting nucleotide biosynthesis, are among the oldest and most widely used cancer treatments, yet resistance remains a daunting barrier, especially in the fight against B cell lymphomas. However, the underlying mechanisms of this resistance have long remained elusive. Using an innovative, integrated omics approach, we unexpectedly identified that the accumulation of dipeptides and upregulation of the dipeptide transporter SLC15A3 underlie resistance to nucleotide deficiency in a Myc -driven large B cell lymphoma mouse model. A similar mechanism occurred after long treatment of human B cell lymphoma cells with the chemotherapeutic purine synthesis inhibitor 6-mercaptopurine (6MP). Mechanistically, we demonstrated that dipeptides containing essential amino acids activated the growth and survival mTOR complex 1 (mTORC1) signaling pathway. Notably, SLC15A3 specifically interacted with mTOR on the lysosome, boosting mTORC1 activity selectively in resistant lymphoma cells but not in parental cancer cells. Silencing SLC15A3 diminished mTORC1 activity and restored resistant lymphoma sensitivity to 6MP. Strikingly, resistant lymphomas, but not primary tumors, exhibited heightened sensitivity to the clinical mTOR inhibitor, rapamycin, in culture and in vivo. We extended these findings in human lymphoma biopsies, which revealed increased SLC15A3 expression following antimetabolite therapy. Together, our study uncovered a metabolic adaptation that fuels cancer resistance to nucleotide deficiency and positions the mTORC1 inhibitor, rapamycin, as a potential therapeutic strategy for transforming the management of chemotherapy-resistant lymphomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mechanistic Target of Rapamycin Complex 1Drug Resistance, NeoplasmDipeptidesLymphoma, B-CellNeoplasm ProteinsMercaptopurineAmino Acid Transport SystemsAntimetabolites, AntineoplasticAnimalsHumansMiceCell Line, TumorSignal Transduction

Stichwörter der Autor:innen

Drug therapyHematologyLymphomasMetabolismOncology

Substanzen

Mechanistic Target of Rapamycin Complex 1DipeptidesNeoplasm ProteinsMercaptopurineAmino Acid Transport SystemsAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Helen Diller Family Comprehensive Cancer Center, and.
  • Department of Urology, School of Medicine, UCSF, San Francisco, California, USA.
  • Department of Pharmacological Sciences, School of Medicine, Stony Brook University, Stony Brook, New York, USA.
  • Department of Pathology.
  • Department of Neurology, and.
  • Department of Biochemistry & Biophysics, UCSF, San Francisco, California, USA.

Förderung

  • NIA NIH HHS
  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIH

Zitieren

APA

Yang, H., Zingaro, V. A., Boardman, K., Noronha, A., Guney, E., Xue, L., Hoigebazar, S., Liu, I., Miglani, S., Chen, S., Vu, H., Wen, K. W., Nguyen, H. G., Goodarzi, H., DeBerardinis, R. J., & Ruggero, D. (2026). SLC15A3-mediated dipeptide metabolism confers antimetabolite resistance in lymphoma via mTORC1 activation. Journal of Clinical Investigation, 136(14). https://doi.org/10.1172/jci199709

Vancouver

Yang H, Zingaro VA, Boardman K, Noronha A, Guney E, Xue L, et al. SLC15A3-mediated dipeptide metabolism confers antimetabolite resistance in lymphoma via mTORC1 activation. Journal of Clinical Investigation. 2026;136(14). doi:10.1172/jci199709

BibTeX
@article{Yang2026,
  author = {Yang, Haojun and Zingaro, Vincenzo Andrea and Boardman, Kevin and Noronha, Ashish and Guney, Ekin and Xue, Lingru and Hoigebazar, Saishma and Liu, Isabelle and Miglani, Sohit and Chen, Siyu and Vu, Hieu and Wen, Kwun Wah and Nguyen, Hao G and Goodarzi, Hani and DeBerardinis, Ralph J and Ruggero, Davide},
  title = {SLC15A3-mediated dipeptide metabolism confers antimetabolite resistance in lymphoma via mTORC1 activation},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {14},
  doi = {10.1172/jci199709}
}
Kostenlos starten →